The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) is uncertain. Although observational studies have suggested DAPT for longer than a year post-PCI reduces ischemic events, other studies suggest longer durations of DAPT confer no benefits despite increased bleeding risk. This randomized controlled trial evaluated patient outcomes with 12-months vs 30-months […]
Tag: aspirin
Aspirin use and major bleeding
The American Diabetes Association recommends low-dose aspirin (75-162mg per day) for adults with diabetes and no previous history of vascular disease, but with a 10-year risk of cardiovascular events greater than 10% and who do not have an increased risk for bleeding. However, as the benefits of low-dose aspirin in the primary prevention setting are […]
Modest benefit from aspirin as primary prevention therapy in diabetics
Although several large trials of aspirin for primary prevention have included diabetic subgroups, no trial has been specifically dedicated to looking at the effects of aspirin in this patient group. […]